KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Total Debt (2016 - 2026)

Abbott Laboratories' Total Debt history spans 18 years, with the latest figure at $34.0 billion for Q1 2026.

  • On a quarterly basis, Total Debt rose 157.11% to $34.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $34.0 billion, a 157.11% increase, with the full-year FY2025 number at $12.9 billion, down 8.47% from a year prior.
  • Total Debt hit $34.0 billion in Q1 2026 for Abbott Laboratories, up from $12.9 billion in the prior quarter.
  • Over the last five years, Total Debt for ABT hit a ceiling of $34.0 billion in Q1 2026 and a floor of $12.9 billion in Q4 2025.
  • Historically, Total Debt has averaged $16.2 billion across 5 years, with a median of $15.0 billion in 2024.
  • Biggest five-year swings in Total Debt: fell 13.69% in 2024 and later surged 157.11% in 2026.
  • Tracing ABT's Total Debt over 5 years: stood at $16.8 billion in 2022, then fell by 12.48% to $14.7 billion in 2023, then dropped by 3.77% to $14.1 billion in 2024, then dropped by 8.47% to $12.9 billion in 2025, then surged by 163.34% to $34.0 billion in 2026.
  • Business Quant data shows Total Debt for ABT at $34.0 billion in Q1 2026, $12.9 billion in Q4 2025, and $12.9 billion in Q3 2025.